1Attal M, Harousscau JL, Stoppa AM, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.N Engl J Med, 1996,335:91.
2Powles R, Raje N, Milan S, et al.Outcome assessment of a populationbased group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.Bone Marrow Transplant,1997,20:435.
3Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with auto transplants for multiple myeloma. Blood, 1999,93:51.
4Sirmhi B, Powles R, Treleaven J, et al. The role of autologous transplantstion in patients with multiple myelctm aged 65 years and over. Bone Marrow Transplant, 2000,25 : 533.
5Tricot G, Gazitt L, Leemhuis T, et al. Collection, tumor contamination and engraftmentkinetics of highly purified hermatopoietic progenitor cells to support high dose therapy in multiplemyeloma, Blood, 1998;91:4489.
6Fermand JP, Ravaud P, Chevret S, et al. High dose therapy and autologous blood stem cell transplantation in multiple myeloma: upfront or rescue treatmeat? Results of a multicenter sequential randomized clinical trial. Blood,1998,92:3191.
7Bjorkstraad B, Sversson H, Ljungmand P, et al. 2 522 autotransplants in multiple myeloma: Aregistry study from the European Group for Blood and marrow Transplantation (EBMT). Blood, 1997,90:419a(Suppl 1, abstr 1862).
8Atbanasios F, Guido T. Result of high - dose treat with autologous stem cell support inpatients with multiple mydoma. serminars in Hematology, 2001,38:231.
9Lemoli RM, Mardnelli G, Zamagni E, et al. Engraftment, clinical, and molecular follow- up of patients with multiple myeloma who were reinfused with highly purified CD34 cells to support single or tandem high- dose chemotherapy. Blood, 2000,95:2234.
10Gharton G, Tura S, Svensson H, et al. Allogenic bone marrow transplantation in multiple myeloma- an undate of the EBMT registry. Sixth International Workshop on Multiple myeloma. Syclabus Boston, MA, 1997. 114- 118.
